OSAKA, Japan, /PRNewswire/ — Shionogi & Co., Ltd. (hereafter “Shionogi” or “the Company”) announces that the Company has concluded an agreement with Eddingpharm (hereafter “Eddingpharm”) to license-out lusutrombopag, a thrombopoietin receptor agonist (brand name in Japan: MULPLETA®). Read more: https://prn.to/2XONsh1
Anne Wojcicki is 45 minutes late, something so encoded in her habits as 23andMe’s CEO that employees have stopped complaining about it. They know it’s hardwired. Read more: http://bit.ly/2Y3y6sW
Another sizeable cash injection for big data biotech: Sophia Genetics has announced a $77 million Series E funding round, bringing its total raised to $140 million since the business was founded back in 2011. Read more: https://tcrn.ch/2XMmG8Y
一直以來，香港擁有堅實的科技基礎及雄厚的科研實力，更是亞洲頂尖學府、各類研究機構及高水準的專業人員的熔爐。加上，擁有基建配套齊備及政策完善，如低稅政策等先天優勢，孕育出發展蓬勃的生物科技企業生態系統， Read more: http://bit.ly/2Y3sTS0
Cancer sucks, but there are some exciting developments on the research front. In the last month alone, we’ve seen regulators consider a CRISPR therapy that directly targets tumor cells—a first for the U.S. Read more: http://bit.ly/2RereTX
人造肉第一股Beyond Meat於美股上市僅1個月，股價爆升3倍，帶起人造肉熱潮。就連全球最大的食品企業雀巢亦不甘後人，馬上加入人造肉的戰綫，將於今年秋季於美國推出人造肉應市。 Read more: http://bit.ly/2XrVVXN
李嘉誠有份投資的嬰兒益生菌生產商Evolve BioSystems，宣佈旗艦產品Evivo透過Evivo. Read more: http://bit.ly/2wxZeRy
科技素食成為市場新焦點。李嘉誠有份投資的初創公司Impossible Foods宣布最新獲得E輪股權融資注入3億美元（約23億港元）資金，這次E輪融資由現有投資者淡馬錫（Temasek）及李嘉誠旗下的維港投資帶領進行。整輪E輪融資總金額已 Read more: http://bit.ly/2XqsiWR
明報記者 陳惠恩 內地去年限制走資，影響上市公司的估值水平，生物科技股亦同受影響。夏爾巴投資創始人及管理合伙人蔡大慶表示，目前資金流向稍為偏穩，但市場仍盼望有較明顯的放開資金限制。他認為，估值對生物科技 Read more: http://bit.ly/2wzXibn
© 2024 尹思哲 — Powered by WordPress
Theme by Anders Noren — Up ↑